Answers are grounded in this paper and cite their sources.
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.
No takes yet. Share an insight, caveat, or question.
Çeti̇n et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: